XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
  Asthma
  COPD
  Cystic Fibrosis
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

American Journal of Respiratory and Critical Care Medicine

Respiratory Medicine Channel
subscribe to Respiratory Medicine newsletter

Latest Research : Respiratory Medicine

   DISCUSS   |   EMAIL   |   PRINT
Six-minute walk test predicts mortality rates in patients with pulmonary fibrosis
Sep 15, 2006 - 5:46:00 PM, Reviewed by: Dr. Rashmi Yadav

"The six-minute walk test's ability to separate those alive at six months from those who died was not only significantly better than chance, but also superior to the forced vital capacity percent (FVC%) predicted test."

 
For idiopathic pulmonary fibrosis (IPF) patients awaiting lung transplantation, a simple walk test can predict mortality rates. A new study found that individuals with IPF who can cover less than 680 feet during the six-minute test are four times more likely to die than those who can walk greater distances.

The research appears in the second issue for September 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

David J. Lederer, M.D., of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons in New York City, and five associates examined the records of 454 adult IPF patients on U.S. transplantation waiting lists.

In IPF, lung tissue is damaged by an unknown cause. The walls of the air sacs become inflamed, which leads to scarring or fibrosis. As a result, patients with IPF frequently suffer from progressive respiratory failure. Eventually, the scarring causes permanent loss of the lungs' ability to transport oxygen.

To date, lung transplantation is the only medical therapy that has been shown to improve survival. Twenty-percent of all lung transplant procedures performed worldwide involve patients with IPF.

The investigators call the six-minute walk test a "simple, safe, reliable and inexpensive" way to assess the self-paced exercise capacity of IPF patients. It varies little when repeated on the same person over a short period of time.

"A total of 209 patients had a six-month follow-up without undergoing lung transplantation," said Dr. Lederer. "Forty-nine of these patients, 23 percent, died during that time period. The six-minute walk test's ability to separate those alive at six months from those who died was not only significantly better than chance, but also superior to the forced vital capacity percent (FVC%) predicted test."

The authors noted that a lower six-minute walking distance was associated with more severe lung disease, status as a minority and lower educational attainment in a nationwide cohort of patients with IPF who were listed for lung transplantation.

The test also predicted waitlist mortality independently of age, sex, race, lung function indices, presence of pulmonary hypertension and other potential confounders.

According to the investigators, the six-minute walk test has at least four advantages over other tests: 1) it is less costly than other tools; 2) it can be performed on patients with severe hypoxemia (inadequate amounts of oxygen in the blood) who require continuous high-flow oxygen; 3) it can be performed in any sufficiently long hallway by appropriately trained personnel; and 4) it does not require specialized equipment and expertise found only in established pulmonary function laboratories;

The authors concluded that a test like FVC% predicted might not be valid for gauging survival in patients with IPF who have been listed for lung transplantation because of the serious nature of their illness.
 

- The research appears in the second issue for September 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
 

 
Subscribe to Respiratory Medicine Newsletter
E-mail Address:

 

Contact: David J. Lederer, M.D., Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH-8, Room 840, New York, New York 10032
Phone: (212) 342-3739
E-mail: [email protected]


Related Respiratory Medicine News

Acute lung injury is prevented by FoxM1 protein
Six-minute walk test predicts mortality rates in patients with pulmonary fibrosis
A dog in home may worsen asthma in children
Cystic fibrosis-related diabetes is due to functional abnormalities in beta cells
COPD patients using beta-agonist inhalers are at risk
Beta-agonists linked with increased number of respiratory deaths -study shows
Beta-agonists more than double death rate in COPD patients
No evidence for inhaled corticosteroids efficacy in cystic fibrosis
Lung function test underused in patients with COPD
Wrinkles clue to risk of progressive lung disease (COPD)


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us